Hypothesis

We hypothesize that the superior systemic exposure reported for quercetin phytosome formulations stems from enhanced lymphatic uptake of intact quercetin aglycone, bypassing first‑pass glucuronidation. In contrast, isoquercetin’s apparent low plasma AUC reflects rapid intestinal hydrolysis to quercetin followed by extensive hepatic glucuronidation; however, a fraction of the glucuronide is deconjugated in target tissues by β‑glucuronidase activity associated with senescent cells, locally regenerating active aglycone. This tissue‑specific reactivation could explain senolytic efficacy despite modest circulating levels.

Mechanistic Rationale

• Phytosome pathway: Lipid‑complexation promotes incorporation into chylomicrons, directing quercetin into the lymphatic circulation. Lymphatic delivery avoids portal venous hepatic uptake, reducing immediate glucuronidation and preserving aglycone in plasma (3).
• Isoquercetin pathway: As a glucoside, isoquercetin is efficiently absorbed via SGLT1, then hydrolyzed by cytosolic β‑glucosidases to quercetin aglycone within enterocytes. The liberated aglycone undergoes rapid UDP‑glucuronosyltransferase (UGT) mediated glucuronidation, yielding quercetin‑3‑O‑glucuronide that appears in portal blood (2).
• Tissue reactivation: Senescent cells overexpress lysosomal β‑glucuronidase as part of the senescence‑associated secretory phenotype (SASP). This enzyme can cleave quercetin glucuronides, releasing free aglycone locally where it can exert senolytic actions (4).
• Threshold consideration: The senolytic threshold of 10–20 µM free quercetin may be achieved in tissue microenvironments even when plasma concentrations remain below this level, due to focal deconjugation.

Testable Predictions

1. Plasma pharmacokinetic profiles will show higher AUC₀₋₂₄ and Cmax for quercetin phytosome versus isoquercetin, with phytosome exhibiting a longer Tmax consistent with lymphatic absorption.
2. Isoquercetin administration will result in elevated plasma quercetin‑3‑O‑glucuronide levels, but tissue (e.g., adipose, liver) quercetin aglycone concentrations will be detectable and correlate with β‑glucuronidase activity.
3. Inhibition of hepatic UGTs (using a low dose of probenecid) will increase plasma quercetin aglycone levels after isoquercetin dosing without affecting phytosome pharmacokinetics.
4. Pharmacological blockade of lysosomal β‑glucuronidase (with a selective inhibitor) will attenuate senolytic effects of isoquercetin in vivo, while having minimal impact on phytosome‑derived quercetin.

Experimental Design

• Study design: Randomized, crossover trial in healthy volunteers (n=24) receiving single oral doses of 500 mg quercetin phytosome, 500 mg isoquercetin, and 500 mg quercetin aglycone (control) separated by 1‑week washout.
• Sampling: Serial blood draws (0‑48 h) for LC‑MS/MS quantification of free quercetin, quercetin‑3‑O‑glucuronide, and isorhamnetin metabolites. Concurrent collection of peripheral blood mononuclear cells and subcutaneous adipose tissue via biopsy at 4 h and 24 h post‑dose for aglycone measurement and β‑glucuronidase activity assay.
• Intervention arms: Sub‑cohorts receive either probenecid (to inhibit UGTs) or a lysosomal β‑glucuronidase inhibitor prior to isoquercetin dosing to test predictions 3 and 4.
• Outcome measures: Primary – AUC₀₋₂₄ and Cmax of free quercetin in plasma. Secondary – tissue aglycone concentrations, β‑glucuronidase activity, and ex vivo senolytic potency (using irradiated human fibroblast senescence assay).

Potential Implications

Confirming lymphatic preference for phytosome would justify its use when rapid systemic aglycone exposure is desired (e.g., acute antioxidant support). Demonstrating that isoquercetin relies on microbial deglycosylation and tissue‑specific glucuronidase activity would suggest that its efficacy depends on gut microbiome composition and senescent cell burden, opening avenues for personalized dosing or microbiome‑modulating adjuvants. Either outcome resolves the current pharmacokinetic gap and directs future formulation strategy toward either enhanced lymphatic delivery or targeted tissue reactivation.